Lisa Moneymaker Elected Vice Chair of ACRO Board of Directors

December 13, 2023Saama, a provider of AI-based solutions that accelerate clinical development and commercialization, is pleased to share that Lisa Moneymaker, the company’s Chief Technology Officer and Chief Product Officer, has been elected Vice Chair of the Association of Clinical Research Organizations’ (ACRO) Board of Directors, effective January 1, 2024.

Moneymaker brings to ACRO’s Board leadership her more than 20 years of experience across the pharma, biotech, and medical device industries with a focus on using technology to improve the quality and safety of clinical research.

“Lisa has dedicated her career to improving clinical trials through the use of innovative technologies that can deliver real-time insights to clinical research teams,” said Vivek Sharma, Chief Executive Officer, Saama. “She brings this first-hand experience to our customers and understands the challenges and opportunities they face when evolving their systems to benefit from modern, AI-driven drug development. As the incoming ACRO Board Vice Chair, Lisa will continue to shape the future of the industry and the adoption of technologies that are driving this change.”

ACRO represents the world’s leading contract research organizations and technology companies whose expertise and innovations play a key role in optimizing biomedical product development, enabling the delivery of better medicines to patients.  

“Continued progress in science and technology presents the opportunity to reshape our approach to clinical research in ways not previously possible,” said Moneymaker. “ACRO provides us the opportunity to both collaborate and challenge one another as we advocate for advancements that can drive safe, effective, and efficient clinical research that brings innovative treatments to patients, faster.”

ACRO announced its 2024 officers and new members this week. The full press release can be viewed here

About Saama

Saama develops life science solutions that accelerate the delivery of therapies to patients. With innovative AI technologies, Saama drives breakthrough intelligence into clinical and commercial operations. The Saama platform powered the clinical trial that led to the world’s first COVID-19 vaccine. Headquartered in Campbell, CA, with employees around the globe, Saama is committed to helping customers save and improve lives. Discover more at


Kate Mikus
Senior Director, Engagement Marketing
[email protected] 

Heather Shea
Catalytic Agency on behalf of Saama
[email protected] 

Recommended Reading